India formulations, which contributed 36% of Q1 consolidated revenue, was the fastest-growing segment. Sales rose 16% year-on-year to ₹5,475 crore, led by cardiovascular (CVD), central nervous system (CNS) and gastro-ortho therapies. Around 40% of the growth came from higher volumes and 20% from new launches, indicating healthy prescription gains.
About The Author
